Whitfield Advises KalVista on $1.9 Billion Acquisition by Chiesi
Overview
Chiesi agreed to acquire KalVista Pharmaceuticals through a cash tender offer, with an implied transaction value around $1.9 billion, the source reports.
Shareholder consideration
The offer price was $27 for each outstanding KalVista share. Both companies' boards were described as unanimously supporting the agreement.
Expected timing
The parties anticipated completion during the third quarter of 2026, subject to closing requirements; the announcement itself does not confirm completion.
Named advisers
Graham Robinson and Chadé Severin are among the corporate advisers listed, alongside finance, capital markets, tax, benefits, intellectual-property, healthcare and competition specialists.
